These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8511035)

  • 1. Molecular and cellular biology of antigen presentation.
    Charron DJ; Lottean V
    Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):25-8. PubMed ID: 8511035
    [No Abstract]   [Full Text] [Related]  

  • 2. Antigen processing and presentation.
    Safley SA; Ziegler HK
    Immunol Ser; 1994; 60():115-30. PubMed ID: 8251564
    [No Abstract]   [Full Text] [Related]  

  • 3. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells.
    LeMaoult J; Krawice-Radanne I; Dausset J; Carosella ED
    Proc Natl Acad Sci U S A; 2004 May; 101(18):7064-9. PubMed ID: 15103024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen presenting cells and HLA-G--a review.
    McIntire RH; Hunt JS
    Placenta; 2005 Apr; 26 Suppl A():S104-9. PubMed ID: 15837058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly conserved, potential cleavage sites about the desetopes of MHC class I and class II molecules.
    Lam V; Thomas LJ; Kostyal DA; Humphreys RE
    Tissue Antigens; 1992 Jan; 39(1):26-31. PubMed ID: 1542874
    [No Abstract]   [Full Text] [Related]  

  • 6. Endocytosis mechanisms and the cell biology of antigen presentation.
    Burgdorf S; Kurts C
    Curr Opin Immunol; 2008 Feb; 20(1):89-95. PubMed ID: 18249105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Umbilical cord blood-naive T cells but not adult blood-naive T cells require HLA class II on antigen-presenting cells for allo-immune activation.
    Kloosterboer FM; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
    Hum Immunol; 2004 Apr; 65(4):328-39. PubMed ID: 15120187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen presentation. Later for the rendezvous.
    Hackett CJ
    Nature; 1991 Feb; 349(6311):655-6. PubMed ID: 1996135
    [No Abstract]   [Full Text] [Related]  

  • 9. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
    Muczynski KA; Anderson SK; Pious D
    J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-presenting cells and the selection of immunodominant epitopes.
    Blum JS; Ma C; Kovats S
    Crit Rev Immunol; 1997; 17(5-6):411-7. PubMed ID: 9419428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Class I and II major histocompatibility complex molecules (HLA system). Antigenic presentation and cellular implications of this presentation].
    Tamouza R; Suberbielle-Boissel C; Charron D
    Rev Prat; 1998 Nov; 48(18):2045-50. PubMed ID: 9881017
    [No Abstract]   [Full Text] [Related]  

  • 12. Fc receptors for IgG and antigen presentation on MHC class I and class II molecules.
    Amigorena S; Bonnerot C
    Semin Immunol; 1999 Dec; 11(6):385-90. PubMed ID: 10625592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular and cellular bases of antigen presentation and autoimmunity].
    Charron D; Ju LY; Teisserenc H; Loiseau P; Lotteau V
    Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):269-72. PubMed ID: 8337142
    [No Abstract]   [Full Text] [Related]  

  • 14. Toward a molecular explanation for cross-presentation of antigens to the immune system.
    Khor B; Makar RS
    Transfus Med Rev; 2008 Jul; 22(3):188-201. PubMed ID: 18572095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?
    Altomonte M; Fonsatti E; Visintin A; Maio M
    Oncogene; 2003 Sep; 22(42):6564-9. PubMed ID: 14528281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving DNA vaccine potency via modification of professional antigen presenting cells.
    Hung CF; Wu TC
    Curr Opin Mol Ther; 2003 Feb; 5(1):20-4. PubMed ID: 12669466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical chaperones enhance superantigen and conventional antigen presentation by HLA-DM-deficient as well as HLA-DM-sufficient antigen-presenting cells and enhance IgG2a production in vivo.
    Ghumman B; Bertram EM; Watts TH
    J Immunol; 1998 Oct; 161(7):3262-70. PubMed ID: 9759841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multiple routes of MHC-I cross-presentation.
    Ramirez MC; Sigal LJ
    Trends Microbiol; 2004 May; 12(5):204-7. PubMed ID: 15120138
    [No Abstract]   [Full Text] [Related]  

  • 19. Class I and class II antigens in the rejection of murine islet cell transplants.
    Hauptfeld V; Lacy PE; Graff RJ
    Transplant Proc; 1995 Dec; 27(6):3234-5. PubMed ID: 8539929
    [No Abstract]   [Full Text] [Related]  

  • 20. Antigen processing. Transporters of delight.
    Parham P
    Nature; 1990 Dec 20-27; 348(6303):674-5. PubMed ID: 2259379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.